Medisys
This article was originally published in The Gray Sheet
Executive Summary
Plans to use majority of $4.2 mil. in expected net proceeds from a stock offering for final development and preliminary sales and marketing of Sofceps, an obstetrical tractor designed to replace traditional steel obstetrical forceps. In a Securities and Exchange Commission filing for the proposed offering of 1 mil. shares at $5 each, the company notes that the product will be ready for human clinical trials no sooner than three months after the realization of the proceeds. Following the offering, which is being underwritten by Grady and Hatch & Co., there will be approximately 10.7 mil. shares outstanding. Recent bid and ask prices for the stock cited in the March filing were $3.13 and $3.63, respectively.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.